@Sirwes
Thanks for that. It sort of fits in with what many posters here have been suspecting for some time. It would be expected that at some point, when the success of some lines begin to outshine the others (Vaxinia, AzerCel, Oncarlytics and PD1 Vaxx), they will take priority and the others will command less attention and ultimately less funding. Let it be licensed out if they can achieve that. Putting all the attention into the surviving 4 will allow better focus IMO.
This is heating up now so onward - 2024 looking to be a great year.
IMU product line - HER-Vaxx, page-26
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
0.005(9.26%) |
Mkt cap ! $433.6M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.9¢ | 5.4¢ | $1.489M | 25.99M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 35252 | 5.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.0¢ | 1753430 | 24 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |